Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab +/- Domvanalimab in Resectable MMRd/MSI-H Gastric/GOJ Adenocarcinoma
NCT06250036Phase 2Suspended
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Started Feb 2025; status: suspended.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250036.